Short Description
Measures NAG activity, a renal damage marker.
Development Stage
Research-Grade Protein & Enzyme Assay Development
Description
The ModifiSite™ β-N-Acetylglucosaminidase Assay Kit provides a sensitive urinary biomarker for detecting early-stage renal tubular toxicity in pharmaceutical development. This high-throughput compatible assay allows for the non-invasive monitoring of kidney injury during nephrotoxicity screening. It is an essential component of safety panels, ensuring that new drug candidates do not cause sub-clinical renal damage.
Features
High-throughput compatible; Sensitive urinary biomarker for early-stage renal tubular toxicity in drug development.
Process Relevance
Early Kidney Injury Biomarker
Application Stage
Pre-clinical Safety
Applications
Early detection of renal tubular damage and nephrotoxicity.
Qualified With
Internal performance validation using reference standards under defined assay conditions.
Detection Method
Absorbance at 405 nm
Sample Type
Urine, serum, plasma, cell lysate, samples
Research Areas
Nephrology (Toxicology)
Datasheet